Highlights Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq Other stock markets 03:59:51 2024-05-30 pm EDT			5-day change	1st Jan Change
1.38 ^USD	-4.83%		-2.82%	-81.22%

May. 07	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	Apr. 09	CI
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	Mar. 27	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	Mar. 14	CI
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	Mar. 11	MT
Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	Mar. 11	CI
Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 01	CI
Immuneering Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 01	CI
Immuneering Receives FDA's Fast Track Designation for IMM-1-104 in Pancreatic Cancer	Feb. 20	MT
Immuneering Shares Rise After FDA Fast-Track Status for Pancreatic Cancer Treatment	Feb. 20	DJ
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	Feb. 20	CI
Immuneering Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference	23-10-12	CI
Immuneering Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
IMMUNEERING CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	23-05-04	AQ
Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Immuneering Corporation Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-Ras Program	23-04-18	CI
IMMUNEERING CORP (form 10-K)	23-03-06	AQ
Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immuneering Corporation

Equities

IMRX

US45254E1073

Highlights

Filters